Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies

We compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in...

Authors:
Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, ..., Skinner SR, et al.

Authors notes:
Journal of Infectious Diseases 210(4): 517-534.

Keywords:
cervical abnormality, HPV, infection, naturally acquired antibodies, risk reduction

Abstract:
We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681).

We compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]).

High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+).

For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated.

Naturally acquired HPV-16 antibody levels of 371, and 480 EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively.

Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.